SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Status:
Completed
Trial end date:
2019-06-17
Target enrollment:
Participant gender:
Summary
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously
untreated AML who are not considered candidates for intensive remission induction
chemotherapy.